Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
125%(5 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_3
3
60%
Ph phase_4
1
20%
Ph phase_2
1
20%

Phase Distribution

0

Early Stage

1

Mid Stage

4

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
3(60.0%)
Phase 4Post-market surveillance
1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(4)
Terminated(1)

Detailed Status

Completed4
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
80.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (20.0%)
Phase 33 (60.0%)
Phase 41 (20.0%)

Trials by Status

terminated120%
completed480%

Recent Activity

0 active trials
Showing 5 of 5
terminatedphase_3

The Paediatric EVICEL® Neuro Study

NCT02309645
completedphase_3

The Paediatric EVICEL® Soft Tissue and Parenchymal Organ Bleeding Study

NCT02227706
completedphase_3

The EVICEL® Neurosurgery Phase III Study

NCT02457546
completedphase_2

The EVICEL® Gastrointestinal Study

NCT01589822
completedphase_4

The Use of Evicel to Reduce Blood Loss in Total Knee Replacement Surgery

NCT01235715

Clinical Trials (5)

Showing 5 of 5 trials
NCT02309645Phase 3

The Paediatric EVICEL® Neuro Study

Terminated
NCT02227706Phase 3

The Paediatric EVICEL® Soft Tissue and Parenchymal Organ Bleeding Study

Completed
NCT02457546Phase 3

The EVICEL® Neurosurgery Phase III Study

Completed
NCT01589822Phase 2

The EVICEL® Gastrointestinal Study

Completed
NCT01235715Phase 4

The Use of Evicel to Reduce Blood Loss in Total Knee Replacement Surgery

Completed

All 5 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
5